Chongqing Yao Pharmaceutical Co., Ltd

What Chongqing Yao Pharmaceutical Co., Ltd does

Chongqing Yao Pharmaceutical Co., Ltd (YaoPharma / 重庆药友制药有限责任公司) is a Chinese pharmaceutical manufacturer founded in 1939 and headquartered in Chongqing's Yubei District. It is the consolidated pharmaceutical manufacturing core of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (Shanghai Stock Exchange 600196), to which Fosun has supplied a controlling stake since 2002. The company develops, manufactures, and sells both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), with a diversified therapeutic portfolio spanning hepatology (notably Hepatitis B treatments such as Heptodin/lamivudine and entecavir), anti-infectives (levofloxacin, teicoplanin, linezolid, and cephalosporins through the Hexin subsidiary), central nervous system agents (olanzapine, risperidone, agomelatine), oncology (sorafenib and a clinical-stage Class 1 candidate YP01001), and osteoporosis (alfacalcidol). Its hepatology franchise alone has reportedly treated more than 2.5 million chronic HBV patients over 22 years.

YaoPharma operates through a vertically integrated group structure with nine manufacturing bases across Chongqing (Shuitu, Changshou, Renhe, Nanan), Chengdu, Suzhou, Wuhan, Beijing, Tieling, and Changde, supported by four proprietary technology platforms: microchannel continuous reaction, impurity separation and synthesis, high-difficulty injection formulations, and controlled / sustained drug delivery. The company was the first Chinese prescription-dosage-form manufacturer to receive Canadian cGMP certification, the first solid-dosage-form line in western China to receive US cGMP certification, and most API products carry US and European cGMP certification. Over 75% of API output is exported to Europe and the United States, and 60%+ of products have achieved dual China-US regulatory filing. The group has accumulated 41 generics passing China's consistency evaluation with nine first-to-market approvals and has placed nine products in national volume-based procurement, while running a 5%-of-revenue R&D budget that supports both new small-molecule programs and the first-in-class oncology candidate.

The business operates three revenue streams. Pharmaceutical product sales (one-time / contract-based) cover APIs and finished dosage forms sold to Chinese hospitals, distributors, retail pharmacies (including JD Health and 1Yao online channels), and direct export channels in Europe and the Americas. Contract manufacturing (OEM-style professional services) is provided through multiple group subsidiaries including Kailin, Hexin, and Shinsun. Licensing and collaboration income is generated through in-licensing foreign assets for the Chinese market and out-licensing proprietary innovations abroad, exemplified by the December 2025 exclusive Pfizer agreement for the oral GLP-1 receptor agonist YP05002 and the May 2026 Zhixiang Jintai agreement for the monoclonal antibody Veritolimab. Pricing is contract-based and not publicly disclosed.

Name

Chongqing Yao Pharmaceutical Co., Ltd

Legal name

重庆药友制药有限责任公司

Website

http://www.yaopharma.com

Company type

Private

Founded year

1939

Operating status

Operating

Headcount range

101–250 employees

Short description

Chongqing Yao Pharmaceutical (YaoPharma) is a Chongqing-headquartered, vertically integrated Chinese pharmaceutical manufacturer and subsidiary of Shanghai Fosun Pharma that develops, produces, and sells APIs and finished dosage forms in hepatology, anti-infectives, CNS, oncology, and osteoporosis to hospitals, distributors, and export markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Active pharmaceutical ingredients
• Finished dosage forms
• Hepatitis B treatments
• Antibiotic formulations
• Contract pharmaceutical manufacturing

Headquarters

HQ city

Yubei

HQ country

China

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Development, manufacturing and sales of active pharmaceutical ingredients (API) and finished dosage forms (formulations) covering therapeutic areas including hepatology, anti-infectives, CNS, and cardiovascular medications. Products are sold both domestically in China and internationally in Europe and America.
2. Contract Manufacturing: Contract manufacturing services for pharmaceutical products, including OEM production arrangements with partners.
3. Licensing and Collaboration: Revenue from in-licensing products for Chinese market and out-licensing domestic innovations internationally, including GLP-1 drugs and monoclonal antibodies.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Chongqing Yao Pharmaceutical is a group-oriented national high-tech pharmaceutical enterprise that develops, manufactures, and sells active pharmaceutical ingredients (APIs) and finished dosage forms across therapeutic areas including hepatology, anti-infectives, CNS, and cardiovascular. The company operates an integrated industry chain covering R&D, manufacturing, and commercialization, with products sold domestically in China and exported to Europe, the United States, and Canada.

Product overview

Chongqing Yao Pharmaceutical Co., Ltd is a group-oriented, nationally recognized high-tech enterprise with a complete pharmaceutical industry chain integrating API and formulation R&D, production, and sales. Founded in 1939, the company operates through two main product lines: APIs (原料药) and Finished Dosage Forms (制剂). Key finished products include liver protectants like 阿拓莫兰 (glutathione), antibiotics such as 可乐必妥 (levofloxacin), CNS products including antipsychotics (奥氮平片, 利培酮片, 阿戈美拉汀片), hepatitis treatments like 贺普丁 (lamivudine) and 慧润 (entecavir), and osteoporosis treatments 立庆 (alfacalcidol). The company also manufactures various injectable products through subsidiaries 合信药业 and 吉洛华制药. Most products are certified for export to European and American markets, with over 60% of products achieving dual China-US registration.

Differentiator

Problem solved

Functional benefit

Brands

• 阿拓莫兰 (Atomolan): Reduced glutathione product brand for liver protection
• 可乐必妥 (Kolebituo)
• 凯莱止 (Kaizhizhi)
• 立庆 (Liqing)
• 贺普丁 (Hepditin)

Products and services

• Atomolan (阿拓莫兰) - Glutathione Products

Quantifiable outcome

• Lamivudine benefited over 2.5 million Chinese chronic hepatitis B patients in 22 years, contributing to 24 million reduction in chronic HBV infections and 4.3 million reduction in HBV-related deaths
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

• Zhixiang Jintai (智翔金泰)coreStrategic or Co-development Partner · 29 May 2026YaoPharma entered into exclusive licensing agreement with Zhixiang Jintai for Veritolimab (纬利妥米单抗) in Greater China region. This partnership provides YaoPharma exclusive rights for this monoclonal antibody product.
• Pfizer Inc.flagshipStrategic or Co-development Partner · 9 December 2025YaoPharma entered into exclusive licensing and cooperation agreement with Pfizer for oral small molecule GLP-1 receptor agonist (GLP-1R) including YP05002. Pfizer granted exclusive rights to YaoPharma for development and commercialization of this innovative diabetes/obesity treatment molecule.
• 1药网 (1Yao)minorChannel Partner/ Reseller/ Distributor · 20 October 2025YaoPharma conducts annual exchange meetings with 1Yao online pharmacy platform to strengthen collaboration in pharmaceutical distribution and consumer health products.
• Asahi Kasei Pharmaceutical (旭化成制药)coreStrategic or Co-development Partner · 1 March 2022YaoPharma signed strategic cooperation agreement with Asahi Kasei Pharmaceutical to explore collaboration opportunities in pharmaceutical development and commercialization.
• Ping An Healthcare (平安健康)minorStrategic or Co-development PartnerCo-organized live streaming events with medical experts to educate public on liver health, hepatitis B prevention and treatment, and other health topics.
• Star Shine Biotechnology (星济生物)minorStrategic or Co-development PartnerYaoPharma participated in Series A financing round of Star Shine Biotechnology, an anti-infective macromolecular drug developer, as a continued investment to support innovation in the anti-infective field.

Scale indicators11 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Tianjin Tianyao Pharmaceutical: Chinese state-owned API and finished-dose manufacturer with comparable cGMP-certified facilities and a focus on anti-infectives and corticosteroids. Closely matches YaoPharma's API-heavy export model and concentration in mature generics.
• Zhejiang Huahai Pharmaceutical: China-based vertically integrated API and finished-dose manufacturer with strong US cGMP certifications and a comparable portfolio of generic cardiovascular and CNS drugs sold in regulated markets. Highly analogous business model spanning API supply to ANDA filings.
• Apeloa Pharmaceutical: Chinese API and formulation manufacturer with FDA/EDQM cGMP-certified facilities, large-scale intermediate and finished-dose capacity, and a strong export footprint to Europe and the US — closely matching YaoPharma's API-to-finished-dose dual China-US strategy.
• Zhejiang Hisun Pharmaceutical: Major Chinese API and specialty finished-dose manufacturer with FDA-approved facilities and a heavy export orientation (US, Europe, Japan). Comparable on cGMP-certified API scale, generics pipeline, and partnerships with multinational pharma.
• China Grand Pharmaceutical and Healthcare Holdings: Hong Kong-listed Chinese pharma with API manufacturing, finished-dose capabilities, and licensing/in-licensing of innovative assets — closely mirroring YaoPharma's hepatitis, anti-infective, and CNS franchises plus its licensing-led growth strategy.

Broad incumbents

• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma with strong CNS and anti-infective franchises plus innovative biologics. Direct overlap in olanzapine/risperidone-class products and similar cGMP-driven export orientation.
• Shanghai Fosun Pharmaceutical (Group): Controlling shareholder of YaoPharma and one of China's largest A+H-listed pharmaceutical conglomerates with a comparable API + formulation + international licensing model. Direct overlap in therapeutic areas (hepatitis B, anti-infectives, CNS) and the same cGMP-driven export strategy.
• Shanghai Pharmaceuticals Holding: One of China's largest state-linked pharmaceutical groups with a full API-to-formulation value chain and significant distribution scale. Comparable on vertical integration and breadth of therapeutic areas, though far larger and more distribution-led.
• Sinopharm Group: China's dominant pharmaceutical distributor and manufacturer with extensive hospital and retail channels. Comparable in API/formulation manufacturing scale and in driving generic drug penetration through national distribution.
• Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharma with a sizable generics and international business. Overlaps with YaoPharma in CNS (olanzapine, risperidone) and oncology generics and is a relevant benchmark for innovation pipeline scale and international expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chongqing Yao Pharmaceutical Co., Ltd